notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: June 23, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–17093 Filed 7–11–95; 8:45 am] BILLING CODE 4160–01–F

[Docket No. 93F-0244]

National Starch and Chemical Co.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 3B4385) proposing that the food additive regulations be amended to provide for the safe use of starch, modified by treatment with diethylaminoethylchloride, hydrochloride salt and 2-chloro-*N*-(2,2-dimethoxyethyl)-*N*-methylacetamide as an internal sizing for paper and paperboard intended to contact food.

FOR FURTHER INFORMATION CONTACT: Mitchell A. Cheeseman, Center for Food Safety and Applied Nutrition (HFS–217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3083.

SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of August 12, 1993 (58 FR 42977), FDA announced that a food additive petition (FAP 3B4385) had been filed by National Starch and Chemical Co., Finderne Ave., Bridgewater, NJ 08807. The petition proposed to amend the food additive regulations in § 178.3520 Industrial starch-modified (21 CFR 178.3520) to provide for the safe use of starch, modified by treatment with diethylaminoethylchloride, hydrochloride salt (CAS Reg. No. 869– 24-9) and 2-chloro-N-(2,2dimethoxyethyl)-N-methylacetamide (CAS Reg. No. 69184-36-7) as an internal sizing for paper and paperboard intended to contact food. National Starch and Chemical Co. has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: June 23, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–17097 Filed 7–11–95; 8:45 am] BILLING CODE 4160–01–F

[Docket No. 89F-0111]

Rhone-Poulenc, Inc.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to future filing, of a food additive petition (FAP 9B4140) proposing that the food additive regulations be amended to provide for the safe use of alkyl (C_{14} – C_{30}) benzene as a component of adhesives for articles intended to contact food.

FOR FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3086.

SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of May 2, 1989 (54 FR 18700), FDA announced that a food additive petition (FAP 9B4140) had been filed by Rhone-Poulenc, Inc., 1669 Corporate Rd. West, Lakewood, NJ 08071. The petition proposed to amend the food additive regulations in § 175.105 Adhesives (21 CFR 175.105) to provide for the safe use of alkyl (C₁₄-C₃₀) benzene as a component of adhesives for articles intended to contact food. Rhone-Poulenc, Inc., has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: June 23, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95-17091 Filed 7-11-95; 8:45 am] BILLING CODE 4160-01-F

Health Care Financing Administration

Statement of Organization, Functions, and Delegations of Authority; Office of the Actuary

Part F of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, Health Care Financing Administration (HCFA), (**Federal Register**, Vol. 59, No. 60, pp. 14643–14644, dated Tuesday, March 29, 1994) is amended to reflect changes in the substructure of the Office of the Actuary (OACT). The OACT functional statement has not been changed; however, the remaining OACT substructure is being published to reflect the organizational changes resulting from streamlining efforts.

The specific amendments to Part F are as follows:

- Section F.10.C.4. (Organization) is amended to read as follows:
 - 4. Office of the Actuary
- a. Office of Medicare and Medicaid Cost Estimates
 - b. Office of National Health Statistics
- Section F.20.C.4. (Functions) is amended by modifying office statements and deleting the office substructure in their entirety. The new functional statements read as follows:

a. Office of Medicare and Medicaid Cost Estimates (FKC1)

- Prepares cost estimates for the Hospital Insurance (HI) program, the Supplementary Medical Insurance (SMI) program, and the Medicaid program for use in the President's budget.
- Evaluates the operations of the Medicare trust funds particularly relating to outlays and program solvency.
- Develops such variables as the Part B premium rates, the inpatient hospital deductible, the Part A premium rate for voluntary enrollees, and the physicians' economic index applicable to prevailing fees
- Develops the payment rates for the annual update of the adjusted average per capita cost (AAPCC) ratebook, which is used to pay health maintenance organizations that enter into a risk contract with HCFA to provide benefits to Medicare enrollees.
- Provides cost estimates for the Medicaid program, including the development of cost estimates for proposed changes in Medicaid or in programs affecting Medicaid, and overall Medicaid program costs for years after the current budget year.
- Serves as technical consultant throughout the Government on Medicare and Medicaid cost estimate issues.
- Provides actuarial consultation to other organizations in the research of AAPCC methodology.

b. Office of National Health Statistics (FKC2)

• Develops, maintains and makes analytical use of the National Health Accounts (NHA) which include annual estimates and publication of National Health Expenditures (NHE) and periodic estimates and publication of NHE by age groupings or by region.

- Provides technical support for HCFA regulatory processes, especially those related to payment systems or reform.
- Develops, analyzes and publishes, health sector models and associated estimates which allow assessments of historical relationships and projections of current law or evaluation of the impact of proposed changes to the current system.
- Plans and manages the Medicare Current Beneficiary Survey. Provides all the in-house activities needed for survey management, data analysis, and coordination and information dissemination.
- Conducts and evaluates surveys containing information relevant to the health care system.
- Maintains, updates and revises the provider market basket input price indexes and the Medicare Economic Index

Dated: June 12, 1995.

Bruce C. Vladeck,

Administrator, Health Care Financing Administration.

[FR Doc. 95–16977 Filed 7–11–95; 8:45 am] BILLING CODE 4120–01–P

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given to amend the notice of the National Cancer Advisory Board Subcommittee on Activities and Agenda meeting which was published in the **Federal Register** (60 FR 33425) on June 28, 1995 to add a closed session.

The Subcommittee meeting is scheduled to be open on July 14, 1995 from 9 am to approximately 2:30 pm. In accordance with provisions set forth in sec. 552b(c)(9)(B), Title 5, U.S.C., and sec. 10(d) of Pub. L. 92–463, the meeting will be closed from approximately 2:30 pm to adjournment for discussion of pending confidential budget matters. These discussions could disclose information, the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action.

Dated: July 6, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95–16991 Filed 7–11–95; 8:45 am] BILLING CODE 4140–01–M

National Cancer Institute; Notice of Closed Meetings

Pursuant to Sec 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Purpose/Agenda: Review, discussion and evaluation of individual grant applications.

Committee Name: Cancer Clinical Investigations Review Committee.

Contact Person: Dr. John Meyer, Executive Plaza North, Room 611C, Telephone: (301) 496–7721.

Date of Meeting: July 25–26, 1995.

Place of Meeting: Hyatt Regency Bethesda,
One Bethesda Metro Center, Bethesda, MD
20814.

Time: 8 am.

Committee Name: Subcommittee B of the Cancer Centers and Research Programs Review Committee.

Contact Person: Dr. Mary Fletcher, Executive Plaza North, Room 643A, Telephone: (301) 496–4964.

Date of Meeting: August 2, 1995. Place of Meeting: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Time: 8:30 am.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: June 30, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95–16990 Filed 7–11–95; 8:45 am] BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Meeting

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the following Heart, Lung, and Blood Special Emphasis Panel.

The meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

Name of Panel: NHLBI SEP on Tissue Engineering.

Dates of Meeting: July 25–26, 1995. Time of Meeting: 1 p.m.

Place of Meeting: Holderness School, Plymouth, New Hampshire.

Agenda: The panel will review the current status of research in the designated areas, identify gaps and make recommendations regarding opportunities and priorities for future contract or grant solicitations.

Contact Person: Paul Didisheim, M.D., Rockledge Building II, 6701 Rockledge Drive, Room 9180, Bethesda, Maryland 20892–7940, (301) 435–0513.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: July 5, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, National Institutes of Health.

[FR Doc. 95–16984 Filed 7–11–95; 8:45 am] BILLING CODE 4140–01–M

National Institute on Deafness and Other Communication Disorders; Amended Notice of Meeting

Notice is hereby given of a change in the July 13, 1995, meeting of the Communication Disorders Review Committee, which was published in the **Federal Register** on June 26, 1995, 60 FR 32987.

The name of the Committee was incorrect. The correct name of the Committee is the National Institute on Deafness and Other Communication Disorders Special Emphasis Panel.

(Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders)

Dated: July 5, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, NIH.

[FR Doc. 95–16992 Filed 7–11–95; 8:45 am] BILLING CODE 4140–01–M

National Institute on Deafness and Other Communication Disorders; Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel.